Reimagining Study Performance Through Education

SCRS SITES NOW

COLLABORATE FORWARD

JUNE 22, 2021

Sites NOW Pharmaceutical Supporters

abbvie

AstraZeneca

Boehringer Ingelheim

Bristol Myers Squibb™

gsk

janssen
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

Lilly

Pfizer

Roche

SANOFI

Sites NOW CRO Supporters

Sites NOW Solution Provider Supporters

Sites NOW @ Work!







Reimagining Study Performance Through Education

Doug Schantz	Vice President, Clinical Operations, Alexion
Michele Cameron	Director of Clinical Research, Clearwater Cardiovascular Consultants
Philip Bedrin	Director of Medical & Clinical Learning Strategy & Solutions, ScienceMedia
Robert Geckeler	Product Director, ScienceMedia

SCRS SITES NOW

COLLABORATE FORWARD

JUNE 22, 2021

Study Training Has the Potential to Impact:

- Protocol Compliance
- Patient Safety
- Quality of Study Data

The Risks of Inadequate Training

…are exacerbated in an environment of increasing protocol complexity reliance on decentralized approaches

- Site burden
- Changes in standard procedures
- Patient demographics and considerations



Approaches to Training Have Not Kept Pace

- Many studies continue to rely on outdated training methods
- There is a need for
  - Risk-based focus
  - Flexible access and delivery
  - Lesson reinforcement and ongoing support



Discussion Topics

- What should the goals of study training be?
  and how should these change given increasingly decentralized approaches to study conduct (new skills, etc.)?
- What do you feel makes training most effective?
  - recent experiences with study training – what worked and didn't
  - specific examples that stood out
- What about the ways in which training is delivered? Is there room for improvement?
- What training-related tools or support do Sponsors need to provide that are not addressed adequately at present?